Premium
Validation of cell‐based fluorescence assays: Practice guidelines from the ICSH and ICCS – part III – analytical issues
Author(s) -
Tangri Shabnam,
Vall Horacio,
Kaplan David,
Hoffman Bob,
Purvis Norman,
Porwit Anna,
Hunsberger Ben,
Shankey T. Vincent
Publication year - 2013
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21106
Subject(s) - peripheral blood mononuclear cell , bone marrow , stain , clinical practice , cytometry , medicine , pathology , biomedical engineering , computational biology , staining , flow cytometry , immunology , chemistry , biology , in vitro , biochemistry , family medicine
Clinical diagnostic assays, may be classified as quantitative, quasi‐quantitative or qualitative. The assay's description should state what the assay needs to accomplish (intended use or purpose) and what it is not intended to achieve. The type(s) of samples (whole blood, peripheral blood mononuclear cells (PBMC), bone marrow, bone marrow mononuclear cells (BMMC), tissue, fine needle aspirate, fluid, etc.), instrument platform for use and anticoagulant restrictions should be fully validated for stability requirements and specified. When applicable, assay sensitivity and specificity should be fully validated and reported; these performance criteria will dictate the number and complexity of specimen samples required for validation. Assay processing and staining conditions (lyse/wash/fix/perm, stain pre or post, time and temperature, sample stability, etc.) should be described in detail and fully validated. © 2013 International Clinical Cytometry Society